Prognostic value, localization and correlation of PD-1/PD-L1, CD8 and FOXP3 with the desmoplastic stroma in pancreatic ductal adenocarcinoma

被引:72
|
作者
Diana, Angela [1 ]
Wang, Lai Mun [2 ]
D'Costa, Zenobia [1 ]
Allen, Paul [2 ]
Azad, Abul [1 ]
Silva, Michael A. [3 ]
Soonawalla, Zahir [3 ]
Liu, Stanley [4 ]
McKenna, W. Gillies [1 ]
Muschel, Ruth J. [1 ]
Fokas, Emmanouil [1 ]
机构
[1] Univ Oxford, CRUK MRC Oxford Inst Radiat Oncol, Dept Oncol, Oxford, England
[2] Oxford Univ Hosp NHS Fdn Trust, Dept Pathol, Oxford, England
[3] Oxford Univ Hosp NHS Fdn Trust, Dept Surg, Oxford, England
[4] Univ Toronto, Sunnybrook Hlth Sci Ctr, Sunnybrook Res Inst, Dept Radiat Oncol, Toronto, ON, Canada
关键词
PD-1/PD-L1; CD8; immune; prognosis; pancreatic cancer; Immunology and Microbiology Section; Immune response; Immunity; IMMUNE CHECKPOINT BLOCKADE; T-CELL INFILTRATION; COLORECTAL-CANCER; FLUID SECRETION; NECK-CANCER; TUMOR; THERAPY; IMMUNOTHERAPY; RAT; MICROENVIRONMENT;
D O I
10.18632/oncotarget.10038
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We examined the prognostic value of programmed cell death-1 (PD-1) and its ligand (PD-L1) together with CD8+ tumor-infiltrating lymphocytes (TILs) and FOXP3+ Tregs in resectable pancreatic ductal adenocarcinoma (PDAC) samples treated with adjuvant chemotherapy. Whole-mount FFPE tissue sections from 145 pancreatectomies were immunohistochemically stained for PD-1, PD-L1, CD8 and FOXP3. Their expression was correlated with clinicopathological characteristics, and overall survival (OS), progression-free survival (PFS), local progression-free survival (LPFS) and distant metastases free-survival (DMFS), in the context of stroma density (haematoxylin-eosin) and activity (alpha-smooth muscle actin) and in regard to intratumoral lymphoid aggregates. The median OS was 21 months after a mean follow-up of 20 months (range, 2-69 months). In multivariate analysis, high PD-1+ TILs expression was associated with better OS (p = 0.049), LPFS (p = 0.017) and DMFS (p = 0.021). Similar findings were observed for CD8+ TILs, whereas FOXP3 and PD-L1 lacked prognostic significance. Although TIL distribution was heterogeneous, tumors of high stroma density had higher infiltration of CD8+ TILs than loose density stroma and vice versa (p < 0.001), whereas no correlation was found with stromal activity. Sixty (41.4%) tumors contained lymphoid aggregates and the presence of PD-1+ TILs was associated with better OS (p = 0.030), LPFS (p = 0.025) and DMFS (p = 0.033), whereas CD8+ TILs only correlated with superior LPFS (p = 0.039). PD-1+ and CD8+ TILs constitute independent prognostic markers in patients with PDAC treated with adjuvant chemotherapy. Our study provides important insight on the role of PD-1/PD-L1 in the context of desmoplastic stroma and could help guide future immunotherapies in PDAC.
引用
收藏
页码:40992 / 41004
页数:13
相关论文
共 50 条
  • [41] Prognostic value of PD-L1 overexpression for pancreatic cancer: evidence from a meta-analysis
    Zhuan-Sun, Yongxun
    Huang, Fengting
    Feng, Min
    Zhao, Xinbao
    Chen, Wenying
    Zhu, Zhe
    Zhang, Shineng
    ONCOTARGETS AND THERAPY, 2017, 10 : 5005 - 5012
  • [42] Prognostic value of programmed-death-1 receptor (PD-1) and its ligand 1 (PD-L1) in testicular germ cell tumors
    Cierna, Z.
    Mego, M.
    Miskovska, V.
    Machalekova, K.
    Chovanec, M.
    Svetlovska, D.
    Hainova, K.
    Rejlekova, K.
    Macak, D.
    Spanik, S.
    Ondrus, D.
    Kajo, K.
    Mardiak, J.
    Babal, P.
    ANNALS OF ONCOLOGY, 2016, 27 (02) : 300 - 305
  • [43] The prognostic impact of PD-L1 and CD8 expression in anal cancer patients treated with chemoradiotherapy
    Chan, Angela M. Y.
    Urgoiti, Gloria Roldan
    Jiang, Will
    Lee, Sandra
    Kornaga, Elizabeth
    Mathen, Peter
    Yeung, Rosanna
    Enwere, Emeka K.
    Box, Alan
    Konno, Mie
    Koebel, Martin
    Joseph, Kurian
    Doll, Corinne M.
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [44] Prognostic Value of KRAS Mutation Subtypes and PD-L1 Expression in Patients With Lung Adenocarcinoma
    Tao, Luwei
    Miao, Ruoyu
    Mekhail, Tarek
    Sun, Jingxin
    Meng, Lingbin
    Fang, Cheng
    Guan, Jian
    Jain, Akriti
    Du, Yuan
    Allen, Amanda
    Rzeszutko, Brenda L.
    Socinski, Mark A.
    Chang, Chung-Che
    CLINICAL LUNG CANCER, 2020, 22 (04) : E506 - E511
  • [45] Contemporary clinical trials in pancreatic cancer immunotherapy targeting PD-1 and PD-L1
    Nagaraju, Ganji Purnachandra
    Malla, Rama Rao
    Basha, Riyaz
    Motofei, Ion G.
    SEMINARS IN CANCER BIOLOGY, 2022, 86 : 616 - 621
  • [46] Immunohistochemical analysis and prognostic significance of PD-L1, PD-1, and CD8+tumor-infiltrating lymphocytes in Ewing's sarcoma family of tumors (ESFT)
    Machado, Isidro
    Antonio Lopez-Guerrero, Jose
    Scotlandi, Katia
    Picci, Piero
    Llombart-Bosch, Antonio
    VIRCHOWS ARCHIV, 2018, 472 (05) : 815 - 824
  • [47] Mismatch repair protein and PD-1/PD-L1 expression in pancreatic neuroendocrine neoplasm
    Duan, X. L.
    Hao, S. M.
    Zhao, M.
    Mi, L.
    Shi, J.
    Li, N.
    Yin, X. L.
    Han, X.
    Han, G. J.
    Wang, J. F.
    Li, C. Z.
    Yin, F.
    JOURNAL OF NEUROENDOCRINOLOGY, 2021, 33 : 106 - 106
  • [48] Prognostic Value of Programmed Cell Death 1 Ligand-1 (PD-L1) or PD-1 Expression in Patients with Osteosarcoma: A Meta-Analysis
    Huang, Xin
    Zhang, Weiyue
    Zhang, Zhicai
    Shi, Deyao
    Wu, Fashuai
    Zhong, Binlong
    Shao, Zengwu
    JOURNAL OF CANCER, 2018, 9 (14): : 2525 - 2531
  • [49] PD-1/PD-L1-Associated Immunoarchitectural Patterns Stratify Pancreatic Cancer Patients into Prognostic/ Predictive Subgroups
    Karamitopoulou, Eva
    Andreou, Andreas
    de Mortanges, Aurelie Pahud
    Tinguely, Marianne
    Gloor, Beat
    Perren, Aurel
    CANCER IMMUNOLOGY RESEARCH, 2021, 9 (12) : 1439 - 1450
  • [50] Analysis of PD-L1 promoter methylation combined with immunogenic context in pancreatic ductal adenocarcinoma
    Chen, Xinyuan
    Yu, Shuangni
    Chen, Jie
    Chen, Xianlong
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2024, 73 (08)